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Available online xxxxInactivation of the androgen receptor (AR) pathway by androgen deprivation therapy (ADT) is themainstay
of (metastatic) prostate cancer therapy. Ultimately, the AR pathway will be re-activated despite castrate
levels of circulating androgens. Thereby, maintaining its role even in castration resistant prostate cancer
(CRPC). The recent STAMPEDE and CHAARTED trials showed that docetaxel in combination with ADT in-
creased survival in hormone sensitive prostate cancer patients, suggesting cross-talk between AR signaling
and chemotherapy efﬁcacy. We hypothesized that a similar interaction may also apply for CRPC that is
treated with cabazitaxel. We studied the impact of androgen status on the efﬁcacy, pharmacodynamics
and -kinetics of cabazitaxel in a unique and clinically relevant patient derived xenograft model of castration
resistant disease.We found that cabazitaxel is highly effective in a castrate setting with strongly reduced AR
activation, while tumor growth inhibition by cabazitaxel was completely abolished in the presence of high
AR pathway activity. Moreover, additional experiments showed that intratumoral cabazitaxel levels were
3.5 times higher in tumors from castrated mice as compared to tumors from androgen-supplemented ani-
mals. We conﬁrmed that cabazitaxel pharmacokinetics were not affected by testosterone, suggesting that
androgen status might inﬂuence cabazitaxel tumor uptake directly. This study reveals the impact of andro-
gen status on cabazitaxel efﬁcacy and supports the potential of combination of taxane chemotherapeutics
with AR axis targeting agents.
© 2017 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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The treatment landscape of metastatic castration resistant pros-
tate cancer (mCRPC) has expanded with the introduction of taxanes
(docetaxel and cabazitaxel), second generation androgen receptor
(AR) antagonists and the CYP17A inhibitor abiraterone. Despite sub-
stantial clinical impact, the absolute survival beneﬁt in mCRPC re-
mains limited, additionally cross-resistance between drugs may
affect treatment efﬁcacy (Mezynski et al., 2012). As a result, atten-
tion has been directed towards deﬁning the optimal treatment se-
quence. Recent clinical trial results have shown that combiningen deprivation therapy; CRPC,
emistry; TV, Tumor volume.
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timal approach for metastatic prostate cancer patients. The
CHAARTED and STAMPEDE trials have shown robust overall survival
beneﬁts by combining androgen deprivation therapy (ADT) with do-
cetaxel (James et al., 2016; Sweeney et al., 2015). Of note, prelimi-
nary results have shown that docetaxel without ADT is ineffective
in castrate-naive patients (SPCG12, trial NCT00376792) (Ahlgren et
al., 2016). This might suggest that reducing circulating androgen
levels and androgen receptor activity affects taxane efﬁcacy.
Cabazitaxel is the second-line taxane, which is effective in patients
with disease progression during or after docetaxel (de Bono et al.,
2010). We hypothesized that, similarly to docetaxel, cabazitaxel efﬁ-
cacy could be affected by androgen-induced AR activation. To test
our hypothesis, we evaluated the efﬁcacy of cabazitaxel in a preclin-
ical model of CRPC in the presence or absence of androgens. Since
previous work from our group has shown that reduced intratumoral
taxane concentrations affect treatment activity (de Morree et al.,
2016a), we also studied the effect of hormone manipulation on-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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concentrations.
2. Material and Methods
2.1. Cell Culture
The human prostate CRPC cell line PC346C-DCC-K was established
from the PC346C cell line by long-term culturing in the absence of an-
drogens (Marques et al., 2006, 2005). The AR expressing PC346C-DCC-
K cell line can grow in the absence of androgens, but the AR pathway re-
mains active, as indicated by prostate speciﬁc antigen (PSA) expression
(Supplementary ﬁg. 1a). Cell line authenticity was conﬁrmed by short
tandem repeat analysis with the Promega PowerPlex 16 kit. Cells were
regularly tested for mycoplasma infection, and kept into culture for a
maximum of 25 passages after initiating the castrate resistance
phenotype.Fig. 1. Tumor growthdynamics of the PC346-DCC-K tumormodel, conﬁrms CRPCphenotype. (a
cells and castrated at TV N 150 mm3. The next week, mice were randomized to receive either a
tumor growth of the cabazitaxel (b) and placebo (c) treated tumors (±SEM). The PC346-DC
underlining the CRPC phenotype of this model. Arrow indicates time of cabazitaxel treatment
Please cite this article as: Mout, L., et al., Testosterone Diminishes Caba
Xenograft Model, EBioMedicine (2017), https://doi.org/10.1016/j.ebiom.22.2. Animal Welfare
All animal experiments were approved by the Animal experiment
committee under the Dutch experiments on Animal Act. The current
study is in compliance with the Arrive guidelines.
2.3. Effect of Testosterone on Cabazitaxel Efﬁcacy
Twenty-four athymic male NMRI nude mice (NMRI-Foxn1nu;
Taconic, Ry, Denmark) were subcutaneously inoculated with 5 million
PC346-DCC-K cells, while being anesthetized with isoﬂurane/O2.
Tumor volume (TV)wasmonitored twiceweekly by digital calipers, an-
imals were randomized based on TV at start to ensure homogeneous
groups. Mice were surgical castrated once tumors surpassed a volume
of 150 mm3, during the surgical castration mice were anesthetized
with Ketamine/Medetomidine (75 mg/kg and 1 mg/kg) and analgesia
was provided by Carprofen (5 mg/kg). Six to ten days after castration,) Schematic overviewof the experimental set-up;micewere inoculatedwith PC346-DCC-K
testosterone pellet or treatment control, and either cabazitaxel or placebo. (b, c) Average
C-K tumors (n = 5–6) continued to grow after surgical castration of the mice (day 0),
(b) or placebo control (c).
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Medical) containing testosterone (40 mg), or an empty implant as a
control. During implantation of the silastic pellets mice were anesthe-
tizedwith isoﬂurane/O2. The next day,micewere randomized to receive
either one intraperitoneal injection of cabazitaxel (33 mg/kg, Sanoﬁ) or
placebo (saline). Blood for PSA analysis was sampled (submandibular
vein) at tumor formation and biweekly during the experiment
until sacriﬁce. Plasmawas isolated fromwhole blood samples by centri-
fugation at 6800 g for 10 min, and PSA was analyzed by an
electrochemiluminescence immunoassay. Mice were kept on a 12 h
dark/light cycle, food and water were provided ad libitum. Mice were
sacriﬁced once the tumors surpassed a volume of 1500 mm3, or at
90 days after cabazitaxel. Statistical analysis was performed using either
SPSS (IBM, version 21) or Graphpad prism (Graphpad software, version
5.01), sample size was calculated using G*power (Kiel University, ver-
sion 3.1.9.2) and based on an in vivo pilot study (power of 90%, α =Fig. 2. The efﬁcacy of cabazitaxel is abolished by testosterone supplementation while remaining
for the four treatment groups (n=5–6), survivalwas compared by a log-rank test. Onemice in
SD. PSAwas measured in plasma collected at the end of the experiment and normalized for TV.
were compared by a one-way Anova with a Bonferroni post-test, *** indicates a p-value b0.001
from cabazitaxel treated castrate or testosterone supplemented mice. (d) Scoring of IHC stainin
percentage Ki67 positive cells was compared by a one-way Anovawith a Bonferroni post-test, *
test with a Dunn's post-test, ** indicates a p-value of b0.01 and *** indicate a p value of b0.001
Please cite this article as: Mout, L., et al., Testosterone Diminishes Caba
Xenograft Model, EBioMedicine (2017), https://doi.org/10.1016/j.ebiom.20.01 and effect size of 0.85). Statistical analyses of tumor growth were
performed using SPSS and Graphpad prism.
Tumor tissues were formalin ﬁxed and parafﬁn embedded for im-
munohistochemistry (IHC) analysis of the AR and cell cycle marker
Ki67. In short, 4 μm tissue sections were incubated with primary anti-
AR (1:300, SP107CellMarque) or anti-Ki67 (1:100,MIB-1Dako) and vi-
sualized with DAB/H2O2 (Dako EnVision kit). IHC staining's were
blinded for treatment and scored by two readers, AR staining was
scored by multiplying the percentage positive tumor cells with the
staining intensity score (0–3). Ki67 staining was scored for percentage
positive in the tumor cells.
2.4. Cabazitaxel Uptake
The experimental set-up and group size was similar to the
cabazitaxel efﬁcacy experiment, with the following exception; tumorshigh in castrate mice. (a) KaplanMeier survival curve showing the time till TV 1500mm3
the cabazitaxel groupwas excluded due toweight loss. (b) Normalized PSA (μg/L) levels±
One cabazitaxel treated castrate mice had undetectable PSA levels (b0.1 μg/L). PSA values
. (c) Representative images of the IHC staining of the AR and Ki67 in PC346-DCC-K tumors
g; the percentage positive Ki67 cells ± SEM and the AR nuclear staining score± SEM. The
indicates a p-value b 0.05. The ARnuclear staining scorewas compared by a Kruskal-Wallis
.
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zen and stored in−80 °C. Intratumoral cabazitaxel concentration was
determined by a ﬁve times dilution of tissue in blank human lithium
heparinized plasma (w/v), and homogenized by using a tissue homog-
enizer. Cabazitaxel concentrations were determined by a validated
UPLC-MS/MSmethod and based on themethod as described previously
(deMorree et al., 2016a; de Bruijn et al., 2012), and corrected for tumor
weight. The lower limit of quantitation (LLOQ) was established at
1.00 ng/mL for cabazitaxel in human lithium heparinized plasma. Peak
area ratios of cabazitaxel versus the Internal Standard in human lithium
heparinized plasma were a linear function of the concentration from
1.00 to 500 ng/mL. The within- and between-run precision at four test-
ed concentrations, including the LLQ, were ≤10.1 and ≤10.9%, respec-
tively, while the average accuracy ranged from 97.5 to 110%.
2.5. Cabazitaxel PK
Fourteen non-tumor baring athymicmale nudemicewere castrated,
and seven days later, randomized to receive either a silastic implant
containing testosterone or an empty pellet as a control. Two days later
mice received one bolus injection of cabazitaxel (33 mg/kg), and
blood was sampled from the submandibular vein at the following
time points: 30, 60, 120 and 180 min. Plasma was isolated from whole
blood samples by centrifugation at 6800 g for 10 min. Cabazitaxel con-
centrations were determined by UPLC-MS/MS (de Morree et al.,
2016a; de Bruijn et al., 2012). Sample size was calculated using Gpower
and based on a previous study (de Morree et al., 2016a) (power of 80%,
α= 0.05 and effect size of 0.4).
3. Results
We subcutaneously implanted male immune-deﬁcient mice with
the AR wt and PSA secreting CRPC cell line PC346C-DCC-K (Fig. 1a)
(Marques et al., 2006). The PC346-DCC-K model does not express AR
variants (Supplementary ﬁg. 1a) and shows reduced in vitro response
to the anti-androgen enzalutamide compared to the parental model
(van Soest et al., 2013) (Supplementary ﬁg. 1b). We conﬁrmed the
CRPC phenotype of this model in vivo, as tumors continued to grow
after surgical castration of the mice (Fig. 1b, c). Subsequent treatment
with cabazitaxel induced a near-complete tumor response with none
of the castrate mice reaching the end-point (TV 1500 mm3) (Fig. 2a).
In contrast, tumors in castrate mice that received testosterone supple-
mentation failed to show a response to cabazitaxel treatment, withFig. 3. Testosterone supplementation decreases the intratumoral cabazitaxel concentratio
concentrations were measured in PC346-DCC-K tumors from castrate and testosterone suppl
Mean intratumoral cabazitaxel concentrations (ng/mg tumor) ± SD are plotted, t-test was
testosterone supplemented mice received one bolus injection of cabazitaxel, blood samples
were measured in plasma fraction, mean cabazitaxel concentrations ± SEM (n = 7) are show
Please cite this article as: Mout, L., et al., Testosterone Diminishes Caba
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mice (log-rank P = 0.199). Testosterone supplemented mice had,
even after correcting for tumor volume, increased levels of PSA com-
pared to castrate mice, indicating an active AR pathway in these tumors
(Fig. 2b) (Marques et al., 2010). IHC analysis of cabazitaxel-treated tu-
mors in testosterone-supplementedmice showed high levels of AR pos-
itive cells with strong nuclear staining (Fig. 2c). Moreover, in tumors
from cabazitaxel-treated castrate mice, fewer AR positive cells with
less intense nuclear staining were observed, as well as reduced Ki67
staining (Fig. 2d). To determine a potential mechanism of interaction
we measured intratumoral cabazitaxel levels; drug concentrations
were 3.5 times higher in tumors from castratemice compared to testos-
terone supplemented mice (Fig. 3a; 1.36 ng cabazitaxel/mg tumor
tissue vs. 0.39 ng cabazitaxel/mg tumor tissue, respectively). Pharmaco-
kinetic analysis of cabazitaxel serum levels showed that the systemic
exposure to cabazitaxel was not affected by testosterone supplementa-
tion (Fig. 3b).
4. Discussion
In conclusion, this preclinical study supports recent clinical data of
improved taxane efﬁcacywhen combinedwith ADT. Additionally it pro-
vides a potential mechanism of action by greater intratumoral accumu-
lation of taxanes during ADT. This preclinical study emphasizes the
permanent role of the AR pathway in CRPC and demonstrates its impact
on the antitumor activity of cabazitaxel. We show that response to
cabazitaxel in an AR-positive CRPCmodel can be successfully prolonged
and resistance delayed by concomitant androgen depletion, thereby re-
ducing AR-activation. As reduced cabazitaxel accumulation seems not
to be a consequence of a testosterone-induced change in cabazitaxel ex-
posure, alternatively, testosterone may have an impact on cabazitaxel
accumulation. We have previously shown that docetaxel and
cabazitaxel uptake is reduced by knockdown of SLCO1B3 (de Morree
et al., 2016b). Interestingly, OATP drug transporters (encoded by the
SLCO family) are also known to function as steroid transporters
(Green et al., 2017). Further studies are underway to unravel themolec-
ular mechanisms that link the testosterone to the cellular cytotoxic ef-
fect of cabazitaxel. The current study was performed in a unique CRPC
tumor models that retained its AR expression upon castration (or tes-
tosterone-free culture conditions), which allows us to study the role of
the AR in cabazitaxel efﬁcacy. Most hormone sensitive prostate cancer
cell lines cultured in the absence of androgens lose their AR expression,
and are therefore unﬁt to examine the interplay between the AR andn, but does not alter the cabazitaxel pharmacokinetics. (a), Intratumoral cabazitaxel
emented mice, tumors were excised seven days after cabazitaxel treatment (33 mg/kg).
used to compare the concentrations, ** indicates a P-value of 0.0031. (b), Castrate or
were drawn at four time-points (30, 60, 120 and 180 min). Cabazitaxel concentrations
n.
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5L. Mout et al. / EBioMedicine xxx (2017) xxx–xxxtaxane efﬁcacy. Our data provides a rationale for the combined treat-
ment of cabazitaxel with novel antiandrogen treatments in CRPC pa-
tients with an active AR pathway, in order to maximize efﬁcacy of the
taxane treatment (Sternberg, 2016). Additional studies are warranted
to test whether novel antiandrogen treatment, such as abiraterone
and enzalutamide, indeed increase taxane efﬁcacy. Such studies may
provide guidance to deﬁne the optimal window of opportunity for clin-
ical use of combined treatment of taxanes and antiandrogen agents not
only in castrate-naïve, but also in metastatic CRPC patients.
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